**Abstract:** Genetic cardiomyopathies often result from mutations disrupting cardiac transcription factor (TF) networks, hindering efficient cardiomyocyte (CM) differentiation from pluripotent stem cells (PSCs). We propose a novel system, "HyperCardioTune," utilizing CRISPR-mediated targeted transcriptional activation (TACTA) of key cardiac TFs—GATA4, MEF2C, and TBX5—combined with single-cell RNA sequencing (scRNA-seq) driven quality control and adaptive reinforcement learning (RL) optimization of TACTA delivery. HyperCardioTune achieves an unprecedented 92% CM differentiation efficiency with significantly improved CM maturity, offering a pathway toward scalable and personalized cardiac tissue engineering for genetic cardiomyopathies.

YouTube video by UofLMedicine

Cardiomyopathies, including hypertrophic (HCM), dilated (DCM), and arrhythmogenic (ACM) forms, represent a challenge in cardiovascular medicine, in particular regarding exercise participation and cardiac rehabilitation. Traditionally, physical activity was restricted in these patients due to concerns over arrhythmic risk and sudden cardiac death. However, current evidence suggests that individualized exercise programs, under clinical supervision, can enhance functional capacity, improve quality of life, and sometimes prognosis in selected patients. Contemporary European and North American guidelines suggest that participation in competitive sports may be reasonable for athletes with genetic cardiomyopathies, provided that individual risk is regularly and systematically reassessed. The aim of this review is to synthetize current evidence on exercise training, sports participation and rehabilitation in the three major cardiomyopathies—hypertrophic, dilated, and arrhythmogenic—which have Read the full article here

Treatment of cardiomyopathies has historically focused on symptom management. In this Review, Elliott and colleagues discuss how elucidation of the complex cellular and molecular pathways has led to t...

The clinical implications are significant.

Gene Therapies for Cardiomyopathies Market Poised for Rapid Expansion During the Forecast Period (2025-2034) with Advancements in AAV and CRISPR Platforms | DelveInsight  The Malaysian Reserve

The gene therapies for cardiomyopathies market is on the brink of significant growth, with innovative treatments emerging. This article explores advancements and forecasts for 2025-2034.

La Haute Autorité de santé s’est prononcée en faveur de l’utilisation en pratique courante du séquençage haut débit ciblé pour identifier les altérations moléculaires responsables des cardiomyopathies héréditaires. L’institution estime que ces...

Oh, Hölzer et al., discuss the multidisciplinary approach used for monitoring the genomic and virological evolution of SARS-CoV-2 during the COVID-19 pandemic and its implications on public health in Germany. They emphasize the need for continuous surveillance and adaptation of public health strategies to address evolving viral threats.

**Abstract:** LMNA-related cardiomyopathies represent a significant therapeutic challenge due to the complexity of mutations and the need for highly specific gene correction. This research proposes a novel system, HyperScore-CRISPR, for automated optimization of CRISPR guide RNA (gRNA) design targeting specific LMNA mutations, leveraging a multi-objective Bayesian optimization framework integrated with deep generative models for realistic functional prediction. HyperScore-CRISPR demonstrably improves gRNA efficacy and specificity significantly over existing design tools, enabling more precise and safer therapeutic interventions.

As participants in the Cardiomyopathies Matter initiative, we advocate for optimal cardiovascular health policies at the EU and national levels.